The peptide drug pipeline in 2026

A record year for approvals

Peptide drugs have been around for a century, since insulin, but 2026 has been unusual. Our encyclopedia records ten US approvals so far this year of peptides and their close relatives ¹:

Three things stand out. First, two of the peptides are tablets: icotrokinra, approved for moderate-to-severe plaque psoriasis in adults and adolescents, and enlicitide, approved to lower LDL cholesterol ¹. Peptides are normally destroyed in the gut, which is why almost all of them are injected, so oral peptides for common chronic diseases are a genuine change. Second, the list is not only peptides: orforglipron, Lilly's weight-loss pill, is a small molecule that acts on the same receptor as the GLP-1 peptides, and two of the approvals are antibodies ¹. Our guide to what makes a peptide a peptide explains the difference. Third, several approvals are for rare diseases, where small trials can be enough when nothing else works.

The oral peptide turn

The single biggest technical change in this year's approvals is the arrival of peptides as ordinary tablets. A peptide swallowed whole is usually digested like any other protein in food, so for a century the rule was simple: peptide drugs are injected. Oral semaglutide broke that rule earlier by pairing the peptide with an absorption enhancer, but at the cost of strict instructions about taking it on an empty stomach with little water.

Icotrokinra and enlicitide take a different route. Icotrokinra is a 13-amino-acid peptide engineered to resist digestion and block the interleukin-23 receptor, a target previously reached only by injected antibodies; enlicitide is a macrocyclic peptide, a ring-shaped molecule that is harder for gut enzymes to cut, which blocks PCSK9 ¹. Both were approved for common chronic diseases, psoriasis and high cholesterol, where patients have long had to choose between pills that work less well and injections that work better. Whether these oral peptides displace the injectables will depend on long-term results and price, but the technical barrier has clearly moved. Orforglipron, approved the same spring, shows the competing strategy: skip the peptide altogether and design a small molecule that hits the same receptor ¹.

How big is the pipeline?

Counting a pipeline depends on what you count. We use the international nonproprietary names (INNs) that the World Health Organization assigns to drugs, which follow naming stems: peptides usually end in '-tide', gonadotropin-releasing hormone drugs in '-relin' or '-relix', vasopressin analogues in '-pressin'. Our pipeline tracker takes every INN-named peptide in the ChEMBL database whose highest recorded phase is 2 or more, then checks ClinicalTrials.gov for what is running now ².

As of October 1, 2026, that gives 331 molecules: 205 whose furthest point is phase 2, 48 that have reached phase 3 and 78 that have been approved somewhere ². 267 carry the '-tide' stem. But only 97 have at least one active registered study, 1225 studies in all, and for most of the rest the trail has gone cold ². Among the molecules with active studies, the most advanced running trial is phase 3 for 33, phase 4 for 28, phase 2 for 25 and phase 1 or earlier for 4 ².

Our broader peptide registry, which also includes natural peptides and compounds without INNs, holds 767 rows: 136 approved, 46 at phase 3, 198 at phase 2 and 12 at phase 1, with the rest endogenous peptides or compounds whose development status is unknown ³.

What the active pipeline is aiming at

ChEMBL records a mechanism for most molecules. Among the 97 peptides with an active study, the mechanisms recorded most often are below; 55 have no mechanism recorded ².

GLP-1 receptor agonism leads by a distance, and the GIP and glucagon receptors, the extra targets of tirzepatide, retatrutide and the dual agonists, also appear. The rest is a long tail of established peptide hormone systems, parathyroid hormone for bone, oxytocin and vasopressin, gonadotropin-releasing hormone for cancer and fertility, and melanocortin receptors for appetite and pigmentation. Very few peptides with active studies work by entirely new mechanisms; much of the innovation is in how long a molecule lasts, how it is delivered and which receptors it combines.

The obesity race

Most of the money and attention in late-stage peptide development is in obesity and diabetes. The table lists the leading candidates in our encyclopedia, with the number of phase 3 studies registered for each on ClinicalTrials.gov ^{4 1}:

Retatrutide is the most advanced of the next generation. It activates three receptors, GIP, GLP-1 and glucagon, and Lilly reported in July 2026 that it had succeeded in five phase 3 trials; in TRIUMPH-2, adults with obesity and type 2 diabetes on the highest dose lost an average of 20.8% of body weight over 80 weeks. Lilly says it plans to submit a Biologics License Application in the first quarter of 2027 ⁵. Until then it is investigational: Lilly's own release states that retatrutide cannot be legally sold or marketed for human use ⁵.

CagriSema, Novo Nordisk's weekly combination of semaglutide and the amylin analogue cagrilintide, is the nearest decision. Novo filed it with FDA on December 18, 2025, on the REDEFINE 1 and 2 trials, and expects a decision in late 2026 ⁶. In February 2026 it was reported to have lost a head-to-head trial against tirzepatide ⁶, a reminder that a filing is not a guarantee of a market.

Behind them come Amgen's maridebart-cafraglutide, which hangs two GLP-1 peptides on an antibody that blocks the GIP receptor; Boehringer Ingelheim and Zealand's survodutide; and a wave of amylin drugs, eloralintide, petrelintide and the dual amylin and GLP-1 agonist amycretin ¹. China has moved faster on two: mazdutide was approved there in June 2025 and ecnoglutide in 2026, neither with a US application ¹.

Beyond weight loss

The rest of the pipeline is more varied than the headlines suggest. This year's approvals include rusfertide, a hepcidin mimetic that controls red cell production in polycythaemia vera; bulevirtide, which blocks the receptor hepatitis D uses to enter liver cells; and navepegritide, a long-acting form of the growth peptide CNP for children with achondroplasia ¹. Radioligands, peptides or peptide-like molecules that carry radioactive atoms to tumours, keep expanding: Pluvicto's label was widened in August 2026 to cover earlier-stage prostate cancer, and our entry on vipivotide tetraxetan sets out the trials behind it ¹.

Gut peptides are another cluster. Glepaglutide met its primary endpoint in short bowel syndrome, and apraglutide is in development for the same condition ¹. Not every story ends well: larazotide, once the leading drug candidate for coeliac disease, had its phase 3 trial terminated by its sponsor ¹. Liver disease is a growing target, with pemvidutide given Breakthrough Therapy designation for MASH in January 2026 and survodutide in phase 3 for the same condition ¹.

Readouts due this quarter

Each molecule in our pipeline tracker carries the expected primary completion date of its next registered study. Between October and December 2026, 36 molecule-study pairs have a readout due; the phase 2 and 3 studies among them are below ². A primary completion date is the sponsor's estimate of when the last participant is measured, not a promise that results will be published then, and 5 registered readouts in the tracker are already overdue without an update ².

The list is a reminder of how much of peptide development is incremental: new uses for old drugs, head-to-head comparisons and combinations, rather than new molecules. That is where much of the medical value lies, even if it rarely makes the news.

Who leads

The obesity race has made two companies dominant. Eli Lilly has tirzepatide on the market, orforglipron newly approved, retatrutide heading for filing and eloralintide in phase 3; Novo Nordisk has semaglutide, CagriSema under review, amycretin in development and insulin icodec newly approved ^{1 5 6}. Amgen, Boehringer Ingelheim with Zealand Pharma, and Roche with Zealand are the main challengers, and Chinese developers such as Innovent and Sciwind have reached approval at home first ¹.

Outside obesity, smaller companies built several of this year's approvals. Icotrokinra came out of a collaboration between Johnson & Johnson and Protagonist Therapeutics, a University of Queensland spin-out ⁷; rusfertide, developed as PTG-300, is now marketed by Takeda ¹. Ascendis built navepegritide, known in development as TransCon CNP, as a once-weekly alternative to a daily drug, and Merck's enlicitide is a macrocyclic peptide designed to be swallowed, in a cholesterol-lowering class otherwise given by injection ¹. Academic medical centres dominate the long tail of active studies, testing old peptides in new settings ².

What to watch next

Four events will shape the next twelve months. The FDA decision on CagriSema, expected before the end of 2026, will test whether an amylin and GLP-1 combination can win approval despite trailing tirzepatide head to head ⁶. Lilly's retatrutide filing in early 2027 will open the first review of a triple agonist ⁵. Phase 3 results from the amylin drugs will show whether amylin can stand on its own as a weight-loss target. And real-world uptake of the new oral peptides will show whether patients and payers prefer a daily tablet to a weekly or monthly injection.

How to read pipeline news

Three cautions help. Databases lag. ChEMBL, which our tracker and registry draw on, records the highest phase a molecule has reached, and it can take months to catch up with an approval. As we write, it still lists 3 of this year's approvals (rusfertide, enlicitide, navepegritide) as not yet approved; our encyclopedia entries, which are checked against Drugs@FDA, are the more current source ^{3 1}.

Phases are not probabilities. A compound in phase 3 has passed earlier tests, but phase 3 is where many fail, as larazotide and taspoglutide did, and a filing can still end in a refusal or a narrower label ¹. Our article on elamipretide's approval shows how narrow an approval can be.

In the pipeline does not mean available. Retatrutide, CagriSema's cagrilintide and other late-stage compounds are already sold online by research-chemical sellers. Those products are not the drugs in the trials, they are not approved, and their quality is unknown; Lilly states plainly that retatrutide cannot be legally sold for human use ⁵. Our guide to spotting a fake certificate of analysis explains why a seller's paperwork does not close that gap.

Frequently asked questions

What new peptide drugs were approved in 2026?

Our encyclopedia records ten US approvals of peptides and close relatives so far in 2026, including icotrokinra (Icotyde) and enlicitide (Lipfendra), both tablets, plus navepegritide, bulevirtide, rusfertide and two once-weekly insulins.

When will retatrutide be approved?

It is not approved. Lilly said in July 2026 that it plans to submit a Biologics License Application to FDA in the first quarter of 2027; a decision would follow the review.

When is the FDA decision on CagriSema?

Novo Nordisk filed CagriSema on December 18, 2025 and expects an FDA decision in the fourth quarter of 2026. As of October 3, 2026 it is not approved.

How many peptides are in clinical trials?

As of October 1, 2026, 331 INN-named peptides had reached phase 2 or later in ChEMBL, and 97 had at least one active study on ClinicalTrials.gov.

Related on Grey Peptides

• Peptide pipeline tracker
• Peptide registry
• Regulatory tracker

Sources

1. Grey Peptides encyclopedia: approval details for each entry, checked against Drugs@FDA, EMA and company announcements with the read dates shown on each entry; rusfertide's approval date from Drugs@FDA (NDA 220605), read October 3, 2026.
2. Grey Peptides pipeline tracker data (assets/pipeline-data.json): 331 INN-named peptides at ChEMBL phase 2 or later with live ClinicalTrials.gov status, read October 1, 2026.
3. Grey Peptides peptide registry (assets/registry.json), 767 rows from ChEMBL, openFDA, UniProt, PubMed, PubChem and ClinicalTrials.gov, generated 2026-10-02.
4. Grey Peptides evidence counts (_ops/evidence_counts.json): ClinicalTrials.gov studies by phase for each entry, read October 3, 2026.
5. Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. News release, July 23, 2026. Read October 3, 2026.
6. Clinical Trials Arena. Novo Nordisk's CagriSema bested by Lilly's Zepbound in head-to-head trial. February 23, 2026 (filing December 2025 on REDEFINE 1 and 2, decision anticipated late 2026). Read October 3, 2026.
7. Institute for Molecular Bioscience, University of Queensland. 'Life-changing' psoriasis pill gets FDA approval. April 24, 2026 (icotrokinra developed by Johnson & Johnson with UQ spin-out Protagonist Therapeutics). Read October 3, 2026.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.